Hydroxyurea Generates Nitric Oxide in Human Erythroid Cells: Mechanisms for γ-Globin Gene Activation
Authors:
Open Access
- 1 November 2009
- journal article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 234 (11) , 1374-1382
Abstract
Hydroxyurea (HU) induces fetal hemoglobin synthesis through activation of cyclic guanine monophosphate (cGMP) signaling. Studies in sickle cell patients demonstrated increased circulating nitric oxide (NO) levels after oral HU treatment. However, the direct measurement of NO in erythroid cells and its role in fetal hemoglobin induction have not been defined. Therefore, we quantified the level of nitrate and nitrite (NOx) generated by HU in human erythroid progenitors in the presence of three nitric oxide synthase inhibitors (NOS), including NG-monomethyl-L-arginine (L-NMMA). In addition, cGMP levels were measured in the presence or absence of the pathway inhibitor 1H-( 1 , 2 , 4 )ox-adiazolo(4,3-a)quinoxalin-1-one, which blocks soluble guanylyl cyclase formation. HU treatment increased NOx levels and γ-globin transcription in K562 and primary erythroid cells, which was augmented when HU was combined with L-NMMA. Pretreatment with the cGMP pathway inhibitor reversed γ-gene activation by HU. These data demonstrate the direct stimulation of cellular NO and cGMP signaling in erythroid progenitors by HU as a possible mechanism for γ-globin gene activation.Keywords
This publication has 39 references indexed in Scilit:
- Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell VasculopathyJAMA, 2008
- Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cellsBlood, 2008
- Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailabilityBlood, 2006
- Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves γ-globin activation by CREB1 and ATF-2Blood, 2006
- Rat liver-mediated metabolism of hydroxyurea to nitric oxideFree Radical Biology and Medicine, 2006
- Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapyBritish Journal of Haematology, 2005
- Hydroxyurea reacts with heme proteins to generate nitric oxideThe Lancet, 1996
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- The discovery and development of zileuton: An orally active 5-lipoxygenase inhibitorInternational Journal of Immunopharmacology, 1992
- Induction of Fetal Hemoglobin by Cell-Cycle-Specific Drugs and Recombinant ErythropoietinJournal of Pediatric Hematology/Oncology, 1990